SSE 50 (Shanghai)
Jiangsu Hengrui Pharmaceuticals
China's largest innovative pharmaceutical company, developing oncology, contrast media, and anesthesia prescription drugs. SSE 50 (Shanghai) constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
600276.SS Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21-52.5%'22+3.5%'23-11%'24+19.8%'25+30.7%YTD-3.8%
Money in ▸·
Jiangsu Hengrui Pharmaceuticalsapprox. CN¥22.8B
▸ Money out·
Financials & Segments
- Total revenue · approx. CN¥22.8B (FY2023)
- Segments · Oncology drugs · Contrast agents · Anesthetics & others
Revenue from
No refined links yet.
Pays to
No refined links yet.